Sign up to save your podcasts
Or
Share ASCO 2025: Legend Biotech's CEO Ying Huang discusses new CARVYKTI data at ASCO as well as early stage data for emerging CAR-T targets against solid tumors
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
ASCO 2025: Legend Biotech's CEO Ying Huang discusses new CARVYKTI data at ASCO as well as early stage data for emerging CAR-T targets against solid tumors
He describes long-term data for CARTITUDE-1 and a subset analysis from CARTITUDE-4. Plus, a DLL3 targeting armored CAR and a Claudin 18.2 program.
View all episodes
By BiotechTV
4.3
66 ratings
He describes long-term data for CARTITUDE-1 and a subset analysis from CARTITUDE-4. Plus, a DLL3 targeting armored CAR and a Claudin 18.2 program.
More shows like BiotechTV - News
View all
Motley Fool Money
3,222 Listeners
Odd Lots
1,910 Listeners
The Long Run with Luke Timmerman
124 Listeners
The Readout Loud
324 Listeners
Biotech 2050 Podcast
61 Listeners
All-In with Chamath, Jason, Sacks & Friedberg
9,957 Listeners
Business Of Biotech
86 Listeners
BioCentury This Week
34 Listeners
Business Breakdowns
353 Listeners
Biotech Hangout
19 Listeners
Bloomberg Tech
60 Listeners
BG2Pod with Brad Gerstner and Bill Gurley
512 Listeners
Uncapped with Jack Altman
41 Listeners
The Studio at Kendall Square
0 Listeners
Off-Target Effects with Matt Gline
4 Listeners
Biotech CEO Sisterhood
2 Listeners
BioVenture VoiCes with Chris Garabedian
6 Listeners
Cheeky Pint
48 Listeners